Free Trial
NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

Assertio logo
$0.85 -0.07 (-7.59%)
(As of 11/12/2024 ET)

About Assertio Stock (NASDAQ:ASRT)

Key Stats

Today's Range
$0.82
$0.97
50-Day Range
$0.85
$1.35
52-Week Range
$0.73
$1.80
Volume
1.70 million shs
Average Volume
932,166 shs
Market Capitalization
$81.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25
Consensus Rating
Buy

Company Overview

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
45th Percentile Overall Score

ASRT MarketRank™: 

Assertio scored higher than 45% of companies evaluated by MarketBeat, and ranked 677th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Assertio has received no research coverage in the past 90 days.

  • Read more about Assertio's stock forecast and price target.
  • Earnings Growth

    Earnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Assertio is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Assertio is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Assertio has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Assertio's valuation and earnings.
  • Percentage of Shares Shorted

    6.39% of the outstanding shares of Assertio have been sold short.
  • Short Interest Ratio / Days to Cover

    Assertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving.
  • Dividend Yield

    Assertio does not currently pay a dividend.

  • Dividend Growth

    Assertio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.39% of the outstanding shares of Assertio have been sold short.
  • Short Interest Ratio / Days to Cover

    Assertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving.
  • News Sentiment

    Assertio has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Assertio this week, compared to 3 articles on an average week.
  • Search Interest

    12 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Assertio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Assertio is held by insiders.

  • Percentage Held by Institutions

    48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Assertio's insider trading history.
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

ASRT Stock News Headlines

Assertio Therapeutics (ASRT) Receives a Buy from Lake Street
Assertio Holdings price target lowered to $2.15 from $2.75 at Alliance Global
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
Assertio Reports Third Quarter 2024 Financial Results
See More Headlines

ASRT Stock Analysis - Frequently Asked Questions

Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT stock has decreased by 20.4% and is now trading at $0.8520.
View the best growth stocks for 2024 here
.

Assertio Holdings, Inc. (NASDAQ:ASRT) posted its earnings results on Monday, November, 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The firm had revenue of $29.20 million for the quarter, compared to analyst estimates of $29.29 million. Assertio had a positive trailing twelve-month return on equity of 4.88% and a negative net margin of 261.08%.

Assertio's top institutional shareholders include Empowered Funds LLC (0.45%), Palumbo Wealth Management LLC (0.20%), GSA Capital Partners LLP (0.16%) and Thurston Springer Miller Herd & Titak Inc. (0.05%). Insiders that own company stock include Daniel A Peisert, William Mckee, Heather L Mason, Jeff L Vacirca, Ajay Patel, Sam Schlessinger and Paul Schwichtenberg.
View institutional ownership trends
.

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID).

Company Calendar

Last Earnings
8/07/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/10/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ASRT
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.25
High Stock Price Target
$4.00
Low Stock Price Target
$2.75
Potential Upside/Downside
+281.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-331,940,000.00
Net Margins
-261.08%
Pretax Margin
-203.27%

Debt

Sales & Book Value

Annual Sales
$152.07 million
Cash Flow
$0.73 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
92,285,000
Market Cap
$81.23 million
Optionable
Optionable
Beta
0.83
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ASRT) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners